Here's Why Pacific Biosciences of California Is Surging Today
Shares of Pacific Biosciences of California (NASDAQ: PACB), a purveyor of high-accuracy genomic sequencing kits, is marching higher after reporting second-quarter earnings and a big order from a leading genetic-services provider. The news lifted the stock about 13.7% higher as of 3:42 p.m. EDT on Thursday.
Stripping away significant contractual revenue recorded last year, second-quarter product and service sales rose 17% higher than the same period last year, to $20.1 million. Perhaps more importantly, total operating expenses rose just 13% on the year, which suggests the company is becoming increasingly efficient.
Image source: Getty Images.
Source: Fool.com
Pacific Biosciences of California Inc. Aktie
1,53 €
-12,02 %
Die Community sieht Pacific Biosciences of California Inc. leicht positiv: Mehr Buy- als Sell-Einschätzungen.
Bei einem durchschnittlichen Kursziel von 9 € für Pacific Biosciences of California Inc., wäre dies mehr als eine Verdopplung des aktuellen Kurses von 1.53 €.
